Q’Apel’s Lynx Aspiration Catheter System Launched in United States 

September 10, 2026—Q’Apel Medical, a developer of devices for neurovascular intervention, announced the United States launch of the Lynx aspiration catheter system after receiving FDA clearance.

According to the company, Lynx is a family of catheters to support mechanical thrombectomy for the treatment of patients with acute ischemic stroke caused by vessel occlusion. The unified Lynx platform includes three inner-diameter sizes (0.044, 0.058, and 0.072 inch) for optimal vessel-to-catheter ratios and coaxial compatibility across all sizes.

Q’Apel Medical stated that the Lynx aspiration catheter system delivers the tracking, versatility, navigability, and support required for accessing complex cerebrovascular anatomy. The device provides the flexibility and control needed to efficiently adapt to changing flow dynamics during time-sensitive mechanical thrombectomy procedures.

Built on QLCT, the Q’Apel laser cut tube technology, the Lynx device features a bimetal shaft design intended to balance proximal support with distal flexibility. Its open-spaced nitinol structure aims to provide kink resistance and structural resilience to maintain lumen patency; preserve deliverability; and transmit force effectively, stated the company.

“While every stroke case presents unique anatomical challenges, my goal remains to perform the fastest and safest thrombectomy for every patient,” commented Kaustubh Limaye, MD, in the Q’Apel Medical press release. “The Lynx aspiration catheter system offers three highly trackable catheters, each sized to track through the next, that work seamlessly together. This innovation sets Lynx apart, giving me the flexibility to select the right catheter for the vessel. In stroke, where every minute matters, this can be the difference between a timely save and procedural delays.”